AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03994926
Drug: Cannabis cigarette - 4.0% THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smoked cannabis 4.0% THC
Trial: NCT02392546
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02533648
Drug: 2 capsules of lactose daily for 3 month
RxNorm normalized name: lactose Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of lactose daily for 3 month
Trial: NCT01897441
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01897441
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01897441
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
Trial: NCT01308749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray
Trial: NCT03537924
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Trial: NCT01476046
Drug: GSK1995057 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose
Trial: NCT01476046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose
Trial: NCT00320216
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo group will receive placebo medication.
Trial: NCT03421197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
Trial: NCT01705457
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00424697
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00424697
Drug: GW876008
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00941603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
Trial: NCT03968445
Drug: [18F]DPA-714-PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]DPA-714-PET/MRI
Trial: NCT00004346
Drug: chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004346
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01120327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02289755
Drug: ALLN-177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
Trial: NCT02682264
Drug: CB-03-01 cream, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Trial: NCT01206595
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of SKY0402 administered as a nerve block
Trial: NCT01595750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 500 mcg , 12 weeks of treatment
Trial: NCT02116972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5 mL IA injection
Trial: NCT00002466
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002466
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01329549
Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Trial: NCT01329549
Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Trial: NCT01329549
Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
Trial: NCT00405808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily in the morning
Trial: NCT01421511
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~* TR-701 FA Tablets, 200 mg, orally once daily
Trial: NCT00325442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Trial: NCT02676349
Drug: mFolfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin folinic acid irinotecan 5FU oxaliplatin
Trial: NCT02676349
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
Trial: NCT01746992
Drug: Cyclophosphamide 750mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day 1 in both arms
Trial: NCT02078323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01728324
Drug: BI 207127-placebo: 8-week treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 weeks of placebo treatment
Trial: NCT01728324
Drug: BI 207127: 24-week treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks of active treatment
Trial: NCT01728324
Drug: RBV: 24-week treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks of active treatment
Trial: NCT01728324
Drug: BI 207127: 16-week treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 weeks of active treatment
Trial: NCT02045277
Drug: IDP-118 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT02045277
Drug: IDP-118 Monad HP Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT02045277
Drug: IDP-118 Vehicle Lotion
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03360981
Drug: Incretins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
Trial: NCT00003068
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00158652
Drug: 5FU, Paraplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
Trial: NCT01680406
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01340235
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Severe Dowling Meara EBS patients from 6 months to 8 years old
Trial: NCT02140918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01056315
Drug: GRT3938Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
Trial: NCT01056315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overencapsulated tablets of placebo, 16 weeks treatment.
Trial: NCT00754715
Drug: AZD2516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution administered once orally
Trial: NCT00754715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution administered only once
Trial: NCT01226407
Drug: CG200745
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple administration (IV) over the cycles untile MTD/LTD
Trial: NCT00216021
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Trial: NCT03777579
Drug: JS001，an engineered anti-PD-1 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Trial: NCT03777579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Trial: NCT02242149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Diacerein
Trial: NCT04328064
Drug: Rosuvastatin calcium 40mg
RxNorm normalized name: Rosuvastatin Calcium 40mg Oral tablet
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active drug -Rosuvastatin
Trial: NCT04328064
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg placebo for 12 months
Trial: NCT01423240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily orally in the evening
Trial: NCT01825044
Drug: NeuroSTAT 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
Trial: NCT01825044
Drug: NeuroSTAT 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Trial: NCT01819922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder in capsule, one dose within 5 minutes prior to AM meal
Trial: NCT01054404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (up to 5mL)
Trial: NCT01386099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 12 weeks.
Trial: NCT04015908
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 100mg
Trial: NCT04015908
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 325mg
Trial: NCT01543451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Trial: NCT03769714
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 20mL of 0.9%Normal Saline
Trial: NCT01140399
Drug: Furosemide or Furosemide and Dopamine
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to pharmacological treatment receive~* either intravenous diuretics at escalating doses up to 20 mg/h~* or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m.
Trial: NCT00331786
Drug: nitric oxide-releasing acetylsalicylic acid derivative
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01582152
Drug: TPI287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Trial: NCT00008294
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008294
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00008294
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02805907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00114114
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
Trial: NCT02237495
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
Trial: NCT02508168
Drug: SYR-322MET
RxNorm normalized name: Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
Trial: NCT03593304
Drug: Tablet Pyridoxine hydrochlorid
RxNorm normalized name: pyridoxine hydrochloride Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
Trial: NCT03593304
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
Trial: NCT03593304
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
Trial: NCT00615940
Drug: WX-671
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules taken per os once daily until progression or toxicity
Trial: NCT00615940
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule taken per os once daily until progression or toxicity
Trial: NCT01172288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
Trial: NCT03288584
Drug: Corticosteroid and non-biological agents.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment with corticosteroid and non-biological agents.
Trial: NCT03058458
Drug: PIN201104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV or SC administration
Trial: NCT03058458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV or SC administration
Trial: NCT02436486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, orally, single dose
Trial: NCT02933762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
Trial: NCT02040441
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02040441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02040441
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard diabetes care
Trial: NCT01017796
Drug: N-acetylcysteine and ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
Trial: NCT01536938
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02820610
Drug: Normal saline 0.9 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
Trial: NCT01950481
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral LDK378 750 mg once
Trial: NCT03393013
Drug: KZR-616
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection of KZR-616
Trial: NCT00984802
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution for IV administration single dose.
Trial: NCT02494349
Drug: JLP-1207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
Trial: NCT00374907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
Trial: NCT00856375
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV every 3 weeks
Trial: NCT04370028
Drug: Divaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT02549677
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
Trial: NCT00698126
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study; use of the products as in the normal clinical practice conditions
Trial: NCT03395340
Drug: vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle cream applied as a thin film
Trial: NCT00403702
Drug: Oxane HD [oil-RMN3-mixture]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00403702
Drug: Densiron [(F6H8)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01105871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of normal saline iv bolus
Trial: NCT01927198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927198
Drug: RDEA3170 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927198
Drug: RDEA3170 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02082067
Drug: Ketorolac 30mg
RxNorm normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00708994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
Trial: NCT01927198
Drug: RDEA3170 12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01915849
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 15 mg, 50 mg and 150 mg
Trial: NCT01915849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02582749
Drug: LHRH agonist/antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
Trial: NCT00416767
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416767
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05513612
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT02408146
Drug: fentanyl citrate+ ondansetron hydrochloride + normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02408146
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04294264
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02858193
Drug: SCMC-lys powder 1.35 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments.